Cargando…

Bioinformatics combined with clinical data to analyze clinical characteristics and prognosis in patients with HER2 low expression breast cancer

BACKGROUND: Human epidermal growth factor receptor 2 (HER2) is a landmark protein in determining the targeted treatment of breast cancer (BC). However, the latest research shows that different intensity of HER2 protein expression levels in BC leads to different clinical characteristics, treatment, a...

Descripción completa

Detalles Bibliográficos
Autores principales: Chen, Yongcheng, Ma, Yanfei, Li, Yanghong, Yu, Yanrong, Lu, Bimin, Liao, Liangyan, Li, Fujun, Wen, Zipeng, Jiang, Wenjun, Guo, Pengwei, Fang, Dalang, Lu, Guanming
Formato: Online Artículo Texto
Lenguaje:English
Publicado: AME Publishing Company 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10005990/
https://www.ncbi.nlm.nih.gov/pubmed/36915815
http://dx.doi.org/10.21037/gs-22-747
_version_ 1784905212878651392
author Chen, Yongcheng
Ma, Yanfei
Li, Yanghong
Yu, Yanrong
Lu, Bimin
Liao, Liangyan
Li, Fujun
Wen, Zipeng
Jiang, Wenjun
Guo, Pengwei
Fang, Dalang
Lu, Guanming
author_facet Chen, Yongcheng
Ma, Yanfei
Li, Yanghong
Yu, Yanrong
Lu, Bimin
Liao, Liangyan
Li, Fujun
Wen, Zipeng
Jiang, Wenjun
Guo, Pengwei
Fang, Dalang
Lu, Guanming
author_sort Chen, Yongcheng
collection PubMed
description BACKGROUND: Human epidermal growth factor receptor 2 (HER2) is a landmark protein in determining the targeted treatment of breast cancer (BC). However, the latest research shows that different intensity of HER2 protein expression levels in BC leads to different clinical characteristics, treatment, and prognosis, especially in HER2 low expression patients. Therefore, this study intends to analyze and compare the clinicopathologic features and prognosis of BC patients with low and zero HER2 expression from The Cancer Genome Atlas (TCGA) database and the data collected by our center. METHODS: First, the BC dataset was downloaded from TCGA database, including 345 eligible and with complete clinical information BC patients, to compare the difference between HER2 low expression groups and HER2 zero expression groups and their correlation with estrogen receptor (ER) and progesterone receptor (PR) expression. Then, the clinicopathological data and follow-up of 405 patients with HER2 low expression and HER2 zero expression diagnosed with BC admitted to the Affiliated Hospital of Youjiang Medical University for Nationalities (YJMU) from January 2017 to December 2021 were collected to verify the consistency of the results of the two data sets. RESULTS: Both the clinical samples and the TCGA data showed that the ER and PR rates were higher in the HER2 low expression group compared with the HER2 zero expression group. There were no significant differences in tumor size, lymph node metastasis, distant metastasis, and disease-free survival (DFS). In addition, the data analysis of 405 clinical samples also showed that the HER2 low expression group had a lower 3-year recurrence or metastasis rate compared with the HER2 zero expression group. CONCLUSIONS: Compared with HER2 zero expression, HER2 low patients express more ER and PR, and have less short-term recurrence and metastasis, but there is no obvious difference in DFS between the two groups.
format Online
Article
Text
id pubmed-10005990
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher AME Publishing Company
record_format MEDLINE/PubMed
spelling pubmed-100059902023-03-12 Bioinformatics combined with clinical data to analyze clinical characteristics and prognosis in patients with HER2 low expression breast cancer Chen, Yongcheng Ma, Yanfei Li, Yanghong Yu, Yanrong Lu, Bimin Liao, Liangyan Li, Fujun Wen, Zipeng Jiang, Wenjun Guo, Pengwei Fang, Dalang Lu, Guanming Gland Surg Original Article BACKGROUND: Human epidermal growth factor receptor 2 (HER2) is a landmark protein in determining the targeted treatment of breast cancer (BC). However, the latest research shows that different intensity of HER2 protein expression levels in BC leads to different clinical characteristics, treatment, and prognosis, especially in HER2 low expression patients. Therefore, this study intends to analyze and compare the clinicopathologic features and prognosis of BC patients with low and zero HER2 expression from The Cancer Genome Atlas (TCGA) database and the data collected by our center. METHODS: First, the BC dataset was downloaded from TCGA database, including 345 eligible and with complete clinical information BC patients, to compare the difference between HER2 low expression groups and HER2 zero expression groups and their correlation with estrogen receptor (ER) and progesterone receptor (PR) expression. Then, the clinicopathological data and follow-up of 405 patients with HER2 low expression and HER2 zero expression diagnosed with BC admitted to the Affiliated Hospital of Youjiang Medical University for Nationalities (YJMU) from January 2017 to December 2021 were collected to verify the consistency of the results of the two data sets. RESULTS: Both the clinical samples and the TCGA data showed that the ER and PR rates were higher in the HER2 low expression group compared with the HER2 zero expression group. There were no significant differences in tumor size, lymph node metastasis, distant metastasis, and disease-free survival (DFS). In addition, the data analysis of 405 clinical samples also showed that the HER2 low expression group had a lower 3-year recurrence or metastasis rate compared with the HER2 zero expression group. CONCLUSIONS: Compared with HER2 zero expression, HER2 low patients express more ER and PR, and have less short-term recurrence and metastasis, but there is no obvious difference in DFS between the two groups. AME Publishing Company 2023-02-08 2023-02-28 /pmc/articles/PMC10005990/ /pubmed/36915815 http://dx.doi.org/10.21037/gs-22-747 Text en 2023 Gland Surgery. All rights reserved. https://creativecommons.org/licenses/by-nc-nd/4.0/Open Access Statement: This is an Open Access article distributed in accordance with the Creative Commons Attribution-NonCommercial-NoDerivs 4.0 International License (CC BY-NC-ND 4.0), which permits the non-commercial replication and distribution of the article with the strict proviso that no changes or edits are made and the original work is properly cited (including links to both the formal publication through the relevant DOI and the license). See: https://creativecommons.org/licenses/by-nc-nd/4.0 (https://creativecommons.org/licenses/by-nc-nd/4.0/) .
spellingShingle Original Article
Chen, Yongcheng
Ma, Yanfei
Li, Yanghong
Yu, Yanrong
Lu, Bimin
Liao, Liangyan
Li, Fujun
Wen, Zipeng
Jiang, Wenjun
Guo, Pengwei
Fang, Dalang
Lu, Guanming
Bioinformatics combined with clinical data to analyze clinical characteristics and prognosis in patients with HER2 low expression breast cancer
title Bioinformatics combined with clinical data to analyze clinical characteristics and prognosis in patients with HER2 low expression breast cancer
title_full Bioinformatics combined with clinical data to analyze clinical characteristics and prognosis in patients with HER2 low expression breast cancer
title_fullStr Bioinformatics combined with clinical data to analyze clinical characteristics and prognosis in patients with HER2 low expression breast cancer
title_full_unstemmed Bioinformatics combined with clinical data to analyze clinical characteristics and prognosis in patients with HER2 low expression breast cancer
title_short Bioinformatics combined with clinical data to analyze clinical characteristics and prognosis in patients with HER2 low expression breast cancer
title_sort bioinformatics combined with clinical data to analyze clinical characteristics and prognosis in patients with her2 low expression breast cancer
topic Original Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10005990/
https://www.ncbi.nlm.nih.gov/pubmed/36915815
http://dx.doi.org/10.21037/gs-22-747
work_keys_str_mv AT chenyongcheng bioinformaticscombinedwithclinicaldatatoanalyzeclinicalcharacteristicsandprognosisinpatientswithher2lowexpressionbreastcancer
AT mayanfei bioinformaticscombinedwithclinicaldatatoanalyzeclinicalcharacteristicsandprognosisinpatientswithher2lowexpressionbreastcancer
AT liyanghong bioinformaticscombinedwithclinicaldatatoanalyzeclinicalcharacteristicsandprognosisinpatientswithher2lowexpressionbreastcancer
AT yuyanrong bioinformaticscombinedwithclinicaldatatoanalyzeclinicalcharacteristicsandprognosisinpatientswithher2lowexpressionbreastcancer
AT lubimin bioinformaticscombinedwithclinicaldatatoanalyzeclinicalcharacteristicsandprognosisinpatientswithher2lowexpressionbreastcancer
AT liaoliangyan bioinformaticscombinedwithclinicaldatatoanalyzeclinicalcharacteristicsandprognosisinpatientswithher2lowexpressionbreastcancer
AT lifujun bioinformaticscombinedwithclinicaldatatoanalyzeclinicalcharacteristicsandprognosisinpatientswithher2lowexpressionbreastcancer
AT wenzipeng bioinformaticscombinedwithclinicaldatatoanalyzeclinicalcharacteristicsandprognosisinpatientswithher2lowexpressionbreastcancer
AT jiangwenjun bioinformaticscombinedwithclinicaldatatoanalyzeclinicalcharacteristicsandprognosisinpatientswithher2lowexpressionbreastcancer
AT guopengwei bioinformaticscombinedwithclinicaldatatoanalyzeclinicalcharacteristicsandprognosisinpatientswithher2lowexpressionbreastcancer
AT fangdalang bioinformaticscombinedwithclinicaldatatoanalyzeclinicalcharacteristicsandprognosisinpatientswithher2lowexpressionbreastcancer
AT luguanming bioinformaticscombinedwithclinicaldatatoanalyzeclinicalcharacteristicsandprognosisinpatientswithher2lowexpressionbreastcancer